By admin 
The pharmaceutical marketing landscape is undergoing a profound transformation, driven by the rapid integration of artificial intelligence (AI) into clinical practice. This shift is compelling industry leaders to re-evaluate traditional performance metrics and strategic allocations, moving beyond conventional goals of "share of voice" and "omnichannel reach" towards a new imperative: "share of answer" (SOA). As the healthcare ecosystem increasingly relies on AI for information and decision support, the ability to be cited as an authoritative source by these intelligent systems is becoming paramount for brand influence and ultimately, patient outcomes.
The Dawn of Share of Answer: A Paradigm Shift
For decades, pharmaceutical marketing strategies have largely revolved around maximizing brand visibility and ensuring messages reached healthcare professionals (HCPs) through a diverse array of channels—from medical journals and conferences to sales representatives and digital advertising. This "share of voice" approach measured a brand’s presence in the market, while "omnichannel reach" focused on consistent engagement across multiple touchpoints. However, the advent of sophisticated AI tools, particularly large language models (LLMs), has fundamentally altered how HCPs seek and consume information.
The core challenge now for pharma marketers is not merely to be seen or heard, but to be the definitive, trusted answer when an HCP poses a clinical query to an AI system. This fundamental shift necessitates a departure from impressions-based budgeting towards data-driven investment in AI platforms that directly influence the informational responses clinicians receive. Stephen Onikoro, chief operating officer of PharmaForceIQ, highlighted this critical evolution, stating that marketers cannot simply pour budget into AI ad pitches based on impressions alone and expect effective engagement. Instead, decisions must be rooted in data that reveals where HCPs are seeking answers and what drives their interactions within these new digital frontiers.
HCPs Embrace AI: A New Information Landscape
The widespread adoption of AI by clinicians is no longer a futuristic concept but a present reality. Physicians, like consumers in other sectors, are increasingly incorporating LLMs such as ChatGPT or Claude into their daily professional lives. The convenience, speed, and comprehensive nature of AI-driven information retrieval make these tools indispensable for busy practitioners facing complex clinical questions.
Compelling data underscores this paradigm shift. A survey conducted by the American Medical Association (AMA) revealed that an astounding 81% of U.S. physicians now report using AI tools in clinical practice. This broad adoption signifies that AI is not just a niche interest but a mainstream component of modern medical workflows, spanning various tasks from research and diagnostic support to administrative efficiencies. The implications for how pharmaceutical companies disseminate crucial drug information, clinical trial data, and therapeutic guidelines are immense.
Further substantiating this trend, NBC News reported a striking statistic: in April 2026 alone, 65% of U.S. physicians utilized OpenEvidence across nearly 27 million clinical encounters. OpenEvidence, a specialized AI platform tailored for medical professionals, exemplifies the growing reliance on AI for evidence-based clinical decision-making. This platform’s high engagement rate demonstrates a clear preference among HCPs for AI-powered solutions that provide rapid, synthesised medical information.
Moreover, a global survey of healthcare professionals conducted in March 2026 by IQVIA painted an even clearer picture of AI’s rising influence. It found that 54% of HCPs use generative AI to access scientific information, and a significant 38% rated these AI tools as "critical" or "very important" to their work. Crucially, the survey highlighted that HCPs now place AI above traditional sales representatives as a primary source of clinical information. This finding represents a seismic shift, challenging the long-standing model of direct engagement between pharma sales teams and physicians and underscoring the urgency for marketers to adapt.
Strategic Reorientation: From Impressions to Influence
In response to these developments, pharmaceutical marketers have begun to recalibrate their strategies, with initial efforts largely centered around "answer engine optimization" (AEO). This involves adapting digital content and website structures to be more amenable to AI crawlers, ensuring that proprietary information is easily discoverable and accurately interpreted by LLMs. "The questions have been, what adjustments do we need to make to embed ourselves into the organic flow of these AI engines? How do we adapt our websites to be more amenable to AI crawlers? And they’ve made great strides there," Onikoro noted.
However, the next frontier, according to Onikoro, lies in paid media within AI platforms. "But from a paid-media perspective, 2027 will be huge. Most pharma marketing teams will allocate a sizable portion of their budgets to some type of AI campaign." This projection signals an impending surge in investment in AI-driven promotional efforts.
AI platforms, recognizing this burgeoning market, are actively promoting substantial impressions-based inventory. While the allure of vast reach through these platforms is undeniable, the cost associated with such inventory can be significant. More importantly, investing based solely on impressions, without granular audience data and contextual understanding, carries considerable risk. Many pharma marketers currently face a critical data gap: they lack specific, continuously updated audience insights tailored to AI platforms, which are essential for adapting to evolving HCP behavior and LLM interactions.
Onikoro emphasized this point: "While every platform can likely pitch impressive reach, that reach only matters if your customers are there. If you’re overinvesting in one versus the other, and your physicians are not there, then you’ll get very poor ROI. That makes the data behind those decisions critical." This highlights the imperative for marketers to move beyond surface-level metrics and delve into the specifics of HCP engagement within diverse AI environments.
The Critical Role of Data in Guiding AI Spend
To navigate this complex and rapidly evolving landscape, marketers require robust, reliable data that illuminates HCP activity and guides investment towards the highest returns. This data needs to inform not only where HCPs are seeking information but also precisely what they are seeking and why.
Affinity data, a long-standing tool for informing ad spend, now extends its utility to AI platforms. Companies like PharmaForceIQ are developing sophisticated platforms that dynamically and continuously map affinity data to HCP behavior across both consumer-grade LLMs and specialized clinical AI platforms. This granular insight allows marketers to identify the specific AI tools and ecosystems where their target HCPs are most active and engaged. Furthermore, some clinical platforms enhance data reliability by requiring HCPs to register using their National Provider Identifier (NPI), providing an additional, verifiable signal of professional engagement.
Beyond identifying platform usage, the next level of insight involves understanding the semantic context of HCP queries. "There’s a much deeper level of insight that we are building toward through agent plug-ins," Onikoro explained. These agent plug-ins can be designed to provide authoritative, brand-specific information directly to AI models. When an HCP poses a query, the AI model can reference these pre-approved, expert-validated sources, ensuring that the answer provided is accurate, relevant, and aligned with the brand’s messaging.
This interaction is not a one-way street. The queries themselves—the topics, keywords, and contextual nuances—provide invaluable feedback to marketers. This reciprocal data flow helps refine both where investments are made and the specific types of information that are most valuable and frequently sought by HCPs. This iterative process of data collection, analysis, and strategic adjustment is fundamental to building and maintaining a strong "share of answer."
Navigating the Complexities: Challenges and Ethical Considerations
While the opportunities presented by SOA are immense, the shift also introduces a host of challenges and ethical considerations that pharmaceutical marketers must meticulously address.
- Data Privacy and Security: Handling sensitive HCP and potentially patient-related data within AI platforms demands the highest standards of privacy and security. Compliance with regulations like HIPAA in the U.S. and GDPR in Europe is paramount, requiring robust data governance frameworks and transparent usage policies.
- Accuracy and "Hallucinations": A significant concern with generative AI is its propensity for "hallucinations"—generating plausible but factually incorrect information. In a clinical context, such inaccuracies can have severe patient safety implications. Pharma marketers must ensure that any brand information provided to or through AI models is rigorously vetted, scientifically accurate, and accompanied by appropriate disclaimers. The integrity of medical information cannot be compromised.
- Regulatory Compliance for Promotional Content: The regulatory landscape for AI-driven promotional content is still nascent but rapidly evolving. Health authorities like the FDA and EMA will likely develop stringent guidelines for how pharmaceutical information is disseminated via AI. Marketers must proactively engage with these evolving regulations to ensure all AI-based communications adhere to promotional review standards, including fair balance, risk information, and off-label use considerations.
- Bias in AI Models: AI models are trained on vast datasets, and if these datasets contain inherent biases, the AI’s responses can inadvertently perpetuate them. This could manifest as biased diagnostic suggestions or treatment recommendations. Ensuring the AI systems used are fair, unbiased, and represent diverse patient populations is a critical ethical imperative.
- Cost Versus Value: The high cost of AI inventory, coupled with the nascent nature of SOA measurement, requires marketers to build robust ROI models that move beyond traditional impressions. Demonstrating the tangible value of AI investments in terms of improved HCP engagement, informed prescribing decisions, and ultimately, patient outcomes, will be crucial for securing continued budget allocation.
- Maintaining Human Oversight: Despite AI’s capabilities, human oversight remains indispensable. Medical affairs teams will play a vital role in curating and validating the authoritative content provided to AI models. Sales representatives, while no longer the primary information source, will evolve into expert consultants, building deeper relationships and addressing nuanced queries that AI cannot fully resolve.
The Transformative Potential: New Avenues for Engagement
Despite the complexities, the concept of "share of answer" promises to revolutionize how pharmaceutical companies engage with healthcare professionals. The initial trepidation among marketers facing this constantly changing landscape is understandable. However, with the right data infrastructure and a strategic approach, these decisions can become clearer and unlock unprecedented opportunities.
Onikoro articulated an exciting vision for the future: "For years, marketers have figured out ways to build share of voice across many different channels. Now, AI creates an opportunity to potentially interact one-on-one with an HCP, informing the answers to their specific questions in the same way you would expect a brand marketer or sales rep to respond." This signifies a move towards hyper-personalized, on-demand information delivery, tailored precisely to an individual clinician’s needs at the moment of inquiry.
This evolution is poised to create a more efficient and impactful communication channel between pharma and HCPs. Medical affairs teams, traditionally focused on scientific exchange, will become central to curating the authoritative datasets that feed AI models, ensuring scientific accuracy and compliance. Sales representatives, rather than delivering basic product information, can elevate their roles to focus on complex clinical discussions, patient support programs, and strategic partnerships, leveraging the foundational information provided by AI.
The journey towards fully realizing the potential of share of answer will undoubtedly be an evolution, requiring continuous adaptation, learning, and investment in sophisticated data analytics. However, the next phase is undeniably exciting, offering pharmaceutical marketers a powerful new paradigm to connect and communicate with their customers, fostering deeper engagement and ultimately contributing to better patient care in an AI-powered world. Specialized data platforms, capable of delivering a dynamic, continuously updated view of audience behavior, will be instrumental in enabling marketers to design and execute highly efficient and impactful AI-driven campaigns.
